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Recombinant virusLa Crosse virus is a leading cause of pediatric encephalitis in the Midwestern United States and an emerging
pathogen in the American South. The LACV glycoprotein Gc plays a critical role in entry as the virus
attachment protein. A 22 amino acid hydrophobic region within Gc (1066–1087) was recently identiﬁed as
the LACV fusion peptide. To further deﬁne the role of Gc (1066–1087) in virus entry, fusion, and
neuropathogenesis, a panel of recombinant LACV (rLACV) fusion peptide mutant viruses was generated.
Replication of mutant rLACVs was signiﬁcantly reduced. In addition, the fusion peptide mutants
demonstrated decreased fusion phenotypes relative to LACV-WT. Interestingly, these viruses maintained
their ability to cause neuronal loss in culture, suggesting that the fusion peptide of LACV Gc is a determinant
of properties associated with neuroinvasion (growth to high titer in muscle cells and a robust fusion
phenotype), but not necessarily of neurovirulence.3 West Gates, Hospital of the
elphia, PA 19104-4283, USA.
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La Crosse virus (LACV) is a member of the Bunyaviridae (genus
Orthobunyavirus) and a common cause of pediatric encephalitis and
aseptic meningitis in the Midwestern United States, the principal
location of its major mosquito vector, Ochlerotatus (formerly Aedes)
triseriatus (Thompson et al., 1965). About 300,000 systemic LACV
infections are estimated to occur annually, though fewer than 1.5% of
these are clinically apparent (Kalfayan, 1983). Approximately half of
the children with LACV encephalitis have seizures during the acute
illness, and about 10% will develop epilepsy. A subset of those with
encephalitis (approximately 2%) will have persistent paresis, learning
disabilities, or cognitive defects. It is possible that the incidence of
LACV encephalitis may be under-reported because of clinical
similarities with herpes simplex virus encephalitis (McJunkin et al.,
1998). Importantly, because there is a well developed mouse modelfor LACV encephalitis that mimics many features of the human
disease, LACV infection has been used to study the neuroinvasion and
neurovirulence of arthropod-borne viruses (Janssen et al., 1986).
The LACV genome consists of three single-stranded RNA segments
of negative polarity, designated by size as large (L), medium (M), and
small (S). These segments encode the viral polymerase, two viral
glycoproteins (Gc and Gn) and the nucleocapsid protein, respectively.
In addition, theM and S segments each encode nonstructural proteins,
NSm and NSs. The three negative-stranded RNA segments of the LACV
genome (L, M, and S) have deﬁned roles in virus pathogenesis.
Previous studies have mapped the neuroinvasive phenotype of LACV
to its M RNA segment (Gonzalez-Scarano et al., 1982; Janssen et al.,
1984, 1986; Griot et al., 1993, 1994), whereas at least in one instance,
neurovirulence mapped to the L segment (Endres et al., 1989).
The two M-segment glycoproteins, Gn and Gc, are cleaved co-
translationally from a precursor polyprotein and associate as a
heteromultimer (Bupp et al., 1996; Eshita et al., 1985; Fazakerley
et al., 1988). This Gc/Gn heteromultimer is targeted to the Golgi
apparatus, the site of viral assembly and budding, by a Golgi
localization signal that has been mapped to the carboxy terminus of
Gn (Lappin et al., 1994; Ruusala et al., 1992). Gc is the exclusive target
of neutralizing antibodies against LACV and has been demonstrated to
play a critical role in entry as the virus attachment protein (Pekosz
Table 1
Rescue, growth, and fusion phenotypes LACV Gc (1066–1087) amino acid deletion and
substitution mutant constructs and LACV Gc 761 tryptic site mutant constructs
(Plassmeyer et al., 2007).
Construct Transfer-capable
VLPs generated
rLACV rescue Growth in
BHK-21
FFWI in
BHK-21
rLACV-WT Yes Yes ++++ ++++
W1066A No No
G1067A Yes Yes +++ +
L1074A Yes No
V1076A Yes Yes +++ +
S1077N Yes No
D1078A Yes Yes +++ ++
G1083L No No
Δ1066–1087 No No
SFV FP No No
R761A Yes No
R761H Yes Yes ++ ++++
WT (wild-type LACV M-segment construct used to generate rLACV); VLP (virus-like
particles); FFWI (fusion from within).
++++ WT growth or fusion phenotype where ≥80% of the monolayer is in a
heterokaryon; +++ slight decrease in growth or fusion phenotype (70–80% of
monolayer in a heterokaryon), decrease is not signiﬁcant; ++ impaired growth or
fusion phenotype (50–70% of monolayer is in a heterokaryon, decrease is signiﬁcant
(pb0.001); + severely impaired growth or fusion phenotype, signiﬁcant (b50% of
monolayer is in a heterokaryon).
140 S.S. Soldan et al. / Virology 404 (2010) 139–147et al., 1995b); it is the larger of the two glycoproteins in the genus
Orthobunyavirus. In addition, Gc and recombinant soluble forms that
lack a transmembrane domain form homomultimers and undergo a
pH dependent conformational change that is associated with virus-
cell or cell-to-cell fusion (Pekosz et al., 1995b; Gonzalez-Scarano,
1985; Gonzalez-Scarano et al., 1984).
Previous studies from our group have demonstrated that the
region corresponding to the membrane proximal two-thirds of Gc,
amino acids 860–1442, is critical in LACV fusion and entry
(Plassmeyer et al., 2005; Pekosz et al., 1995a,b); this is consistent
with the previously deﬁned role of Gc as the exclusive target of
neutralizing antibodies generated against LACV. Moreover, compu-
tational analysis identiﬁed structural similarities between the LACV
Gc amino acid region 970–1350 and the E1 fusion protein of two
alphaviruses: Sindbis virus and Semliki Forrest virus (SFV). Collec-
tively, these studies suggested that the LACV Gc functions as a class II
fusion protein, much like the alphavirus E1 glycoprotein and the
ﬂavivirus E glycoprotein, and led to the identiﬁcation of a 22 amino
acid hydrophobic segment (1066–1087) within Gc that was
predicted to correlate structurally with a hydrophobic domain of
SFV and Sindbis virus (Garry and Garry, 2004; Plassmeyer et al.,
2005). This hydrophobic domain is highly conserved among the
Bunyaviridae and closely resembles the fusion domains of SFV E1
and avian sarcoma-leukosis virus (ASLV) E in the placement of its
cysteine residues, which form an internal loop (Levy-Mintz and
Kielian, 1991).
In a subsequent study, we used site-directed mutagenesis of
conserved residues within LACV Gc 1066–1087 to demonstrate that
LACV Gc 1066–1087 functions as the LACV fusion peptide (Plassmeyer
et al., 2007). The effects of mutations within LACV Gc 1066–1087were
assessed using conformational and non-conformational antibodies
speciﬁc to Gc, a luciferase based cell-to-cell fusion assay, and
pseudotype transduction assays (Ma et al., 1999; Plassmeyer et al.,
2005, 2007). Several mutations within this hydrophobic domain
affected glycoprotein expression to some extent, but all mutations
either shifted the pH threshold of fusion below that of the wild-type
protein, reduced fusion efﬁciency, or abrogated cell-to-cell fusion and
pseudotype entry altogether. Notably, a mutation at position 1066
(W1066A) was particularly informative, because it did not affect
glycoprotein expression, yet abrogated fusion and entry. Collectively,
these results support a role for the region Gc 1066–1087, as the LACV
Gc fusion peptide.
Blakqori and Weber developed a three-cDNA plasmid reverse
genetics system for LACV based on a protocol previously estab-
lished for Bunyamwera virus (Blakqori and Weber, 2005). Using
this technology and the existing panel of LACV Gc 1066–1087
fusion peptide mutant constructs, we have generated several
recombinant viruses; we used these recombinant viruses to
examine the effect of mutations in the fusion peptide region on in
vitro growth characteristics, fusion phenotype, and neurotoxicity in
the context of a virus infection in physiologically relevant cells and
cell lines. We found that recombinant viruses with mutations in
LACV Gc (1066–1087) were growth-impaired in muscle cells, insect
cells, and primary rat neuronal cultures and had a diminished
ability to mediate fusion from within (FFWI). As in wild-type virus,
FFWI was pH and temperature dependent in these fusion peptide
mutants. Nevertheless, all fusion peptide mutant rLACVs tested
were as neurotoxic as wild-type virus in primary neuronal cultures
in spite of their decreased growth kinetics and fusion phenotypes;
these data are similar to results obtained with a monoclonal
selected variant virus (V22) with reduced fusion function but
unaltered neurovirulence (Gonzalez-Scarano et al., 1985). Overall,
this study suggests that the fusion peptide of LACV Gc is a
determinant of properties associated with neuroinvasion (growth
to high titer in muscle cells, robust fusion phenotype), but not of
neurovirulence.Results
Generation of recombinant La Crosse virus (rLACV) with speciﬁc
mutations in Gc
We previously generated several mutant LACV Gc constructs
(Plassmeyer et al., 2007). These constructs had either (a) a single
amino acid substitution within LACV Gc (1066–1087), (b) a deletion
of the entire fusion peptide region, LACV (Δ1066–1087), (c) a
substitution containing the entire fusion peptide of SFV instead of
the LACV fusion peptide, LACV (SFV-FP), or (d) a mutation outside the
fusion peptide region, in the tryptic site located at Gc 761 (Table 1).
Although there are many potential proteolytic sites in the Gc
glycoprotein (Gentsch and Bishop, 1979), the tryptic site at position
761 is uniquely accessible in the whole virion prior to acidiﬁcation,
and its accessibility is affected by the conformational changes that are
induced by low pH (Gonzalez-Scarano, 1985). All of the mutations
were engineered into construct pBluescript II KS(+)-LAC(M), then
subcloned into the expression vector pCAGGS (Niwa et al., 1991) and
sequenced for veriﬁcation, as previously described (Plassmeyer et al.,
2005).
Subsequently, these mutant glycoprotein constructs were sub-
cloned into pT7Ribo-LACV-cM and recombinant LACVs (rLACVs) with
mutations in the fusion peptide region were generated. Four
recombinant viruses with targeted mutations in Gc were rescued
from BSR-T7/5 cells using a three-cDNA plasmid system consisting of
the L, S, and mutant M segments in antigenomic orientation,
transcribed by the T7 RNA polymerase (Table 1) (Blakqori and
Weber, 2005). Based on our previous data using constructs containing
these respective mutations in a luciferase based cell–cell fusion assay
(Plassmeyer et al., 2007), these four rLACV Gc mutants represent a
wide range of predicted fusion phenotypes. Namely, one mutant
construct has a normal fusion phenotype (rLACV-R761H), one has a
moderately impaired fusion phenotype (rLACV-G1067A), and two
have severely impaired fusion phenotypes (rLACV-V1076A, and
rLACV-D1078A) (Plassmeyer et al., 2007). We also generated a
control recombinant virus with a wild-type glycoprotein sequence
(rLACV). After repeated attempts, we were not able to rescue viruses
with other speciﬁc mutations in LACV Gc (Δ1066–1087, W1066A,
G1083L, L1074A, S1077N, and R761A), even though some of these
mutant Gc proteins (L1074A, S1077N, and R761A) were capable of
mediating cell-to-cell fusion in a plasmid-based fusion assay
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capable virus-like particles (VLPs) with M-segment constructs
containing these mutations (Fig. 1).
Expression studies of Gc and Gn in cells infected with recombinant virus
To examine cell surface expression of rLACVs in infected cells,
BHK-21 cells (a hamster ﬁbroblastoid cell line) were infected with
LACV or one of the ﬁve recombinant viruses, at a multiplicity of
infection (M.O.I.) of 1.0. Forty-eight hours after infection, the cells
were stained with either conformational monoclonal antibodies
(MAbs) 807-31 and 807-22 against LACV Gc (50:50, vol/vol) or a
commercial MAb against LACV Gn (Abcam, Cambridge, MA).
Expression was then determined by ﬂow cytometry (Fig. 2). These
studies indicated that cells infected with all of the recombinant
viruses expressed both LACV glycoproteins and that Gc is expressed
with apparent conformational integrity. Notably, expression of Gc was
signiﬁcantly decreased in rLACV-R761H, rLACV-G10761 and rLACV-
D1078A infected cells compared to those infected wild-type LACV
(Figs. 2A, B, and E). In addition, Gn expression of the rLACV-R761H
mutant virus was signiﬁcantly decreased compared to wild-type LACV
(Figs. 2C, D, and F). The decreased expression of Gc and Gn in rLACV-
R761H infected cells could reﬂect the reduced replication of this
mutant virus in BHK-21 cells or decreased expression efﬁciency of the
glycoproteins. Similar results were obtained in Hela (human epithe-
lial) and C6/36 (mosquito epithelial-like) cells (data not shown).
Growth kinetics of recombinant virus
The in vitro growth characteristics of the Gc mutant recombinant
viruses were ﬁrst evaluated by a growth curve in BHK-21 cells and
then in cell lines more reﬂective of tissues important in LACV
pathogenesis: muscle cells (G8 cells differentiated in 1% FCS and 1%
horse serum), a mosquito cell line (C6/36), and primary rat neuronal
cultures (prepared from embryonic day 17 Sprague Dawley rat pups
as described previously Brewer, 1995). Replication of rLACV fusion
peptide mutants rLACV-V1076A, rLACV-G1067A, rLACV-D1078A wasFig. 1. Generation of transfer-capable VLPs using LACV M-segment mutant constructs.
VLP transfer of Renilla luciferase with wild-type M-segment constructs was highly
successful. The Fisher's Exact Test was used to compare the number of successful
attempts to produce transfer-capable VLPs from mutant constructs to the number of
successful attempts with the wild-type M-segment construct. VLP production was
achieved for the mutant constructs G1067A, L1074A, V1076A, S1077N, and D1078A;
there were no signiﬁcant differences in the number of attempts that successfully
produced transfer-capable VLPs for G1067A, L1074A, V1076A, S1077N, or D1078A
compared to the number of attempts that generated VLPs using the wild-type M-
segment construct. VLP transfer was unsuccessful for the Δ1066–1087, W1066A, and
G1083L mutant constructs after at least ﬁve attempts (*pb0.01). The inability to
generate VLPs with these constructs is consistent with data demonstrating that these
mutant glycoproteins do notmediate fusion or pseudotype transduction (Plassmeyer et
al., 2007).signiﬁcantly attenuated in differentiated G8 muscle cells (Fig. 3B),
primary rat neuronal cultures (Fig. 3C), and in the mosquito cell line
C6/36 (Fig. 3D) (Student's T test; pb0.001). The tryptic site mutant,
rLACV-R761H grew as well as wild-type LACV and rLACV in these
physiologically relevant cells, even though it replicated less efﬁciently
than wild-type in BHK-21 (Fig. 3A) and in HeLa and 293 T cells (data
not shown). Overall, differences in virus replication were less
pronounced in the reference cell line BHK-21 (Fig. 3A), which
suggests that this in vitro approach will be an appropriate screen
prior to future in vivo experimentation. Importantly, the growth
kinetics of rLACVwere not statistically different from that of LACV-WT
in the cell lines and cell cultures tested, demonstrating that the
recombinant virus is functionally similar to the original isolate.
In vitro characterization of recombinant LACV fusion phenotypes
To determine whether the fusion phenotypes of recombinant
viruses with mutations in the fusion peptide region recapitulate the
ﬁndings in the plasmid-based cell-to-cell fusion assay, we then
performed fusion from within (FFWI) studies in BHK-21, differenti-
ated G8, and C6/36 cells (Plassmeyer et al., 2007). BHK-21,
differentiated G8 cells, and C6/36 cells were infected for 18 h with
LACV or rLACV at a M.O.I. of 1.0. Infected cells and uninfected control
cells were exposed to pH-adjusted medium for 30–60 s, ﬁxed and
then stained for analysis using a Fusion Index (calculated as 1−(C/N)
where C=number of cells and N=number of nuclei— a higher fusion
index represents more fusion).
In BHK-21, differentiated G8 muscle cells, and C6/36 mosquito
cells, fusion indices were similar for wild-type LACV, rLACV and the
tryptic mutant rLACV-R761H (Fig. 4). However, decreased fusion
indices were observed for the three fusion peptide mutants (rLACV-
G1067A, rLACV-V1076A, and rLACV-D1078A), once again supporting a
role for this hydrophobic domain in LACV fusion and entry. Importantly,
the FFWI data obtained with the recombinant LACV is consistent with
previous data from our laboratory testing the fusion efﬁciency of these
mutants in the context of a plasmid-based, cell-to-cell fusion assay
(Plassmeyer et al., 2007). We also treated cells infected with LACV or
the rLACVs with neutralizing antibodies 807-31 and 807-22 after
infection and 18 h prior to exposure to acidiﬁed medium (pH 5.5).
There was a signiﬁcant, dose-dependent decrease in the FFWI induced
by LACV, rLACV and rLACV-R761H when virus spread was inhibited by
anti-LACV neutralizing antibodies (data not shown); the antibodies also
led to a slight decrease in the FFWI induced by the fusion peptide
mutant viruses (rLACV-G1067A, rLACV-V1076A, and rLACV-D1078A),
but the total level of fusion was lower, making a diminution harder to
detect (data not shown).
Temperature dependence of FFWI for recombinant LACV
Previous data from our laboratory has demonstrated a tempera-
ture dependence of FFWI with an optimum temperature of 37 °C. To
determine whether changes in the fusion peptide domain alter the
optimal temperature of FFWI, we performed a FFWI assay in BHK cells
at 4 °C, 23 °C, 35 °C, 37 °C, and 42 °C. As demonstrated in Fig. 5, the
optimal temperature for FFWI for LACV and rLACV, rLACV-R761H, and
rLACV-D1078Amutant recombinant viruses was 37 °C, diminishing at
increased temperatures (42 °C), which is consistent with previous
ﬁndings (Pobjecky et al., 1986). A clear optimal temperature for FFWI
for the rLACV-V1076A and rLACV-G1067A mutants was not apparent,
but that may be because the magnitude of FFWI is comparatively low
for these mutant viruses.
LACV induced neurotoxicity
A MAP2 (microtubule associated protein 2) cell-based ELISA assay
was used to quantify neuronal death as previously described (Wang
Fig. 2. Surface expression of wild-type LACV and recombinant LACV (rLACV) glycoproteins (Gc and Gn) in BHK-21 cells. LACV Gc (A, B, and E) and Gn (C, D, and F) were detected in
BHK-21 cells infected for 48 h at an M.O.I. of 1.0. Expression of Gc was signiﬁcantly decreased in the rLACV-R761H, rLACV-G10761 and rLACV-D1078A infected cells compared to
those infected with wild-type LACV. In addition, Gn expression of the rLACV-R761H mutant virus was signiﬁcantly decreased compared to that of wild-type LACV (*pb0.05,
**pb0.01).
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(rLACV-R761H), and the fusion peptide mutant viruses (rLACV-
G1067A, rLACV-V1076A, and rLACV-D1078A) all induced signiﬁcant
neuronal death asmeasured by decreasedMAP2 staining compared to
MOCK infected cells (Newman–Keuls; pb .05) (Figs. 6A and B).
Interestingly, we did not observe a signiﬁcant increase in neurotox-
icity in LACV or rLACV infected primary rat neuronal cultures
compared to those infected by the rLACV fusion peptide mutant
viruses even though these viruses grew to a higher titer in these cells
(Fig. 3B).Discussion
The availability of a reverse genetics system to generate LACV with
targeted mutations represents an important strategic advance in the
analysis of its neuropathogenesis and, potentially, in the development
of therapeutics and vaccines to prevent infections by LACV and other
bunyaviruses. In this report, we used this system to characterize the
growth characteristics, fusion phenotypes, and neurotoxicity of each
of four rescued Gc LACV mutant viruses. These represent a range of
predicted fusion phenotypes (Plassmeyer et al., 2007): one with a
Fig. 3. Growth kinetics of rLACVs in reference (BHK-21) and physiologically relevant cell lines. BHK-21 (A), differentiated G8 muscle cells (B), primary rat neuronal cultures (C), and
C6/36 cells (D) were infected with wild-type LACV and recombinant viruses at an MOI=0.001. (Infection of primary rat neuronal cultures was initiated at Day in vitro (DIV) 7).
Supernatants from infected cells were harvested at 24, 48, and 72 h post-infection and a standard plaque assay was performed on VERO cells to determine virus replication. Each
curve was performed in triplicate. (*pb0.001 compared to rLACV).
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impaired fusion phenotype (rLACV-G1067A), and two with severely
impaired fusion phenotypes (rLACV-V1076A, and rLACV-D1078A)
(Plassmeyer et al., 2007).
With one exception (rLACV-R761H), the recombinant viruses
replicated similarly in our reference cell lines (Fig. 3A). However, the
fusion peptide mutant viruses (rLACV-V1076A, rLACV-G1067A, and
rLACV-D1078A) were signiﬁcantly attenuated in the muscle cells, in
the insect cells, and even in primary rat neuronal cultures. It is of great
interest that the fusion peptide mutant viruses had impaired growth
phenotypes in the insect cell line and physiologically relevant cells
(G8 muscle cells and primary rat neuronal cultures), but not in BHK-
21 cells. We speculate that the decreased growth kinetics observed in
the G8s and primary rat neuronal cultures may be associated with
terminal differentiation of these cells. Moreover, proteolytic proces-
sing of Gc in the insect vector is extensive and it has been suggested
the role of LACV Gc in fusion and entry in mosquito cells may be
different from that in mammalian cells (Sundin et al., 1987).
Therefore, the consequences of mutations in the fusion peptide region
may not be identical in an invertebrate system. Importantly, the
fusion phenotypes observed for each of the recombinant viruses
mirrored that of their parent Gc construct, validating the relevance of
the plasmid-based cell-to-cell fusion assay and our previous data
(Plassmeyer et al., 2007). Notably we did not observe a discernable
shift in pH activationwith the fusion peptidemutant viruses, although
there was an apparent shift (lower pH activation) in the plasmid-
based cell-to-cell fusion assay using the parent mutant constructs
D1078A, G1067A, and V1076A (Plassmeyer et al., 2007). Paradoxi-
cally, the tryptic mutant R761H had a wild-type fusion phenotype
even in cell lines where its replication was impaired. Although FFWI
did not always correlate with virus replication (Figs. 3 and 4),neutralizing antibodies speciﬁc for Gc were demonstrated to inhibit
both the spread and FFWI of recombinant LACVs (data not shown).
The ability to inhibit both virus replication and fusion with
neutralizing antibodies targeting Gc underscores the importance of
understanding the role of this region in virus pathogenesis.
To understand the effect that changes in the fusion peptide region
may have on neuronal death, a cell property associated with
neurovirulence, we used a MAP2 cell-based ELISA assay that
quantiﬁes neuronal death in primary rat neuronal cultures. We
demonstrated LACV induced neurotoxicity when primary rat neuro-
nal cultures were infected with LACV, rLACV and all of the Gc mutant
rLACVs (rLACV-V1076A, rLACV-G1067A, and rLACV-D1078A). The
degree of neuronal loss was similar in the wild-type and fusion
peptide mutant viruses and did not correlate with virus replication or
the relative ability to mediate FFWI, suggesting that in vitro
neurovirulence may not be directly affected by these changes in the
fusion peptide region. These data may suggest that the neuronal
damage observed in this system may be attributable, in part, to pro-
apoptotic factors, cytokines, and/or excitatory amino acids released
by infected cells and not exclusively caused by direct lysis of LACV
infected neurons.
LACV monoclonal antibody escape variants V22 and V22F,
generated with a monoclonal antibody against Gc (807-22), were
associated with decreased replication in peripheral tissues that are
critical for the generation of a high viremia such as striated muscle;
they also had a decreased ability to mediate cell-to-cell fusion, though
mutations in these viruses were not in the fusion region. Although
these monoclonal antibody escape variants were not neuroinvasive,
owing to the more limited viremia generated, they were as
neurovirulent as the parent LACV when directly injected into the
CNS. In the present study, we have demonstrated that single amino
Fig. 4. FFWI is signiﬁcantly decreased in recombinant virus with changes in the fusion
peptide region. (A) BHK-21 cells, (B) differentiated G8 cells, and (C) C6/36 cells were
infected for 18 h with LACV or rLACVs at an M.O.I. of 1.0. Infected cells and uninfected
control cells were exposed to pH adjusted-medium for 30 to 60 s, ﬁxed, and then
Giemsa-stained. The Fusion Indexwas calculated as 1−(C/N), where C is the number of
cells and N=number of nuclei. FFWI was signiﬁcantly decreased in all recombinant
viruses with changes in the fusion peptide region compared to wild-type LACV and
rLACV (Student's T test; pb0.001). There were n=6 replicates per condition and error
bars represent Standard Error.
Fig. 5. FFWI in BHK-21 cells is temperature dependent. BHK-21 cells were infected with
LACV and recombinant viruses at an M.O.I. of 1.0. FFWI was performed over a range of
temperatures at pH 5.5. There were n=6 replicates per condition and error bars
represent Standard Error of the Mean.
144 S.S. Soldan et al. / Virology 404 (2010) 139–147acid substitutions in the LACV Gc fusion peptide result in a diminished
ability to mediate fusion from within (FFWI) and impaired growth in
muscle cells and in primary rat neuronal cultures. However, these
deﬁciencies in growth and fusion phenotypes do not correlate with
reduced neuronal damage in an in vitro model of neurotoxicity using
primary rat neuronal cultures. It remains to be seen whether in a
mouse model the fusion peptide of LACV Gc will inﬂuence the ability
of the LACV to grow to high titer in peripheral tissues and
subsequently penetrate the CNS, but is ultimately not a determinant
of neurovirulence, but these studies using surrogate cell lines point in
that direction.
In future studies, we will use these recombinant mutant viruses to
address the following questions in the existing mouse model: (a) Will
mutations that affect fusion efﬁciency lead to decreased LACV
replication in key tissues such as muscle and have decreased viremia
and decreased neuroinvasiveness? (b) Conversely, do mutations in
other regions of Gc, like the 761 tryptic site mutant have altered tissue
tropism that increases viremia and neuroinvasion? (c) Will these
fusion peptide mutant viruses be as neurovirulent as the parent LACV
when injected directly into the CNS? (d) Can LACV mutants,
particularly those demonstrated to have impaired neuroinvasive
phenotypes, be used to generate a protective immune response and
serve as the basis for an attenuated virus vaccine? These studies will
serve to further elucidate the role of the LACV fusion peptide region in
the neuropathogenesis of LACV encephalitis. Importantly, because the
fusion peptide region is conserved among the Bunyaviridae (Garry and
Garry, 2004; Plassmeyer et al., 2007), the ﬁndings from this study and
future in vivo experimentationmay be extrapolated to other emerging
bunyaviruses such as Crimean–Congo Hemorrhagic fever virus and
Rift Valley Fever virus with the potential to lead to the development of
therapeutic modalities and vaccines.
Materials and methods
LACV M-segment constructs and site-directed mutagenesis
Fusion peptide mutant LACV M-segment constructs were gener-
ated as previously described (Plassmeyer et al., 2007). Brieﬂy, the
LACV M-segment ORF was subcloned from pcDNA3.1 into the
expression vector pCAGGS (Niwa et al., 1991) to employ the CMV
enhancer and strong chicken β-actin promoter to express the
polyprotein, as previously described (Plassmeyer et al., 2005, 2007).
The LACV M ORF was ampliﬁed using rTth DNA Polymerase XL (PE
Biosystems, Foster City, CA) with a primer set that introduced
restriction cut sites ClaI and XhoI at the 5′ and 3′ ends, respectively.
The PCR cycle consisted of a 93 °C 2 min denaturing step followed by
35 cycles of (93 °C 3 for 0 s, 48 °C for 1 min, 72 °C for 6 min) and an
extension of 72 °C for 10 min. The resulting fragment was digested
with both ClaI and XhoI and inserted into the linearized pCAGGS
expression vector digested with ClaI and XhoI.
To engineer mutations (point, deletion, and insertion of SFV FP) in
the putative fusion domain of LACV Gc and the Gc (761–772) tryptic
site, the LACVM segment was subcloned into pBluescript II KS+ using
ClaI and XhoI (Plassmeyer et al., 2005, 2007). Point mutations were
engineered into the M segment using the QuikChange II XL site-
directed mutagenesis kit following manufacturer's instructions
(Stratagene, La Jolla, CA). The primers used to engineer these
substitutions have been published (Plassmeyer et al., 2007). The
point mutant constructs were then cloned into the expression vector
pCAGGS. TheseM-segment clones were sequenced to verify that there
were no additional mutations.
Generation of fusion peptide mutant rLACVs
rLACV were generated from the above Gc mutant constructs as
described (Blakqori and Weber, 2005). The LACV minireplicon
Fig. 6. Neuronal loss in primary rat neuronal cultures infected with LACV and rLACVs (A) AMAP2 cell-based ELISA assay was used to quantify neuronal death as previously described
(Wang et al., 2007). Infection with wild-type LACV, rLACV, the tryptic mutant (rLACV-R761H), and the fusion peptide mutant viruses (rLACV-G1067A, V1076A, and D1078A) all
induced signiﬁcant neuronal death as measured by decreased MAP2 staining compared to MOCK infected cells (Newman–Keuls; pb .05). Data were collected as arbitrary
ﬂuorescence units and expressed as percent MAP2 positive relative to MOCK infected control. There were n=10 replicates per condition and error bars represent Standard Error of
the Mean. (B) Visualization of LACV infected primary rat neuronal cultures by IFA. FITC (green) = LACV Gc; TRITC (red) = MAP2; Hoecht's (blue). Neuronal damage and loss, as
measured by loss of MAP2 staining, is visible in primary rat neuronal cultures infected with WT LACV, rLAV, the tryptic mutant virus (rLACV-R761H) and the fusion peptide mutant
viruses (rLACV-G1067A, rLACV-V1076A, and rLACV-D1078A).
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expression construct pI.18-LACV M, and the LACV rescue plasmids
pT7Ribo-LACV-cL and pT7Ribo-LACV-cSNoEco were also described
previously (Blakqori et al., 2003; Blakqori and Weber, 2005). The T7-
expressing plasmid pCAGGsT7 was kindly provided by Ramon Flick
(UTMB Texas). The eukaryotic ﬁreﬂy luciferase expression construct
pGL3-control was purchased from Promega. For cloning of the mutant
LACV M virus expression constructs and rescue constructs, M ORF
fragments containing the mutated region were cut out of the
respective pCAGGS constructs using NheI/KpnI digestion, and
inserted into the wild-type M-segment rescue construct pT7Ri-
boSM2-LACV-vM or the eukaryotic expression construct pI.18 LACV
M, respectively, which had been cleaved with the same enzymes.Generation of LACV VLPs
LACV VLPs were generated by a method similar to the one
described for Rift Valley fever virus VLPs (Habjan et al., 2009). Human
Huh7 cells grown in six-well dishes were transfected with 0.25 µg
each of pTM-LACV N, pTM-LACV L and pLACV-vRen along with 0.5 µg
each of pCAGGsT7 and pI.18-LACV M (WT and mutant constructs),
and 0.1 µg pGL3-control, using Nanofectin transfection agent (PAA).
Cells transfected without the M expression constructs served as VLP
negative control. At 48 h post-transfection, supernatants were
harvested and cells were lysed in 200 µl Passive Lysis buffer to
measure Renilla (LACV minireplicon) and ﬁreﬂy (pGL3 control)
luciferase activities using the Dual Luciferase kit (Promega). Cell
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37 °C for 3 h and centrifuged at 12,000 g for 5 min to remove cell
debris. An aliquot of 250 µl cell supernatant was then used to infect 1
well of a 6-well plate of BSR-T7/5 cells (Buchholz et al., 1999) which
had been transfected overnight with 0.25 µg each of the LACV
expression constructs pTM-LACV N and pTM-LACV L. VLP-infected
cells were assayed with the Dual Luciferase system, where Renilla
activity indicated successful VLP infection, and ﬁreﬂy luciferase
indicated background transfection.
Generation of fusion peptide mutant viruses
Recombinant LAC viruses (rLACV) were generated from the above
Gc mutant constructs as described (Blakqori and Weber, 2005).
Brieﬂy, subconﬂuent layers of BSR-T7/5 cells grown in six-well plates
were transfected with 0.5 µg each of plasmids pT7Ribo-LACV-cL,
pT7Ribo-LACV-cSNoEco, and pT7Ribo-LACV-vM (and mutant variants
thereof) using Fugene transfection reagent (Roche). Supernatants
were harvested 5 days later, and 200 µl were used to inoculate Vero
cells for 1 h at 37 °C. After replacing the inoculumwith fresh medium,
Vero cells weremonitored for the appearance of a cytopathic effect for
the next 5 days. wtLACV rescue (rLACV) was always included as
positive control. Virus rescues were attempted 3 times with
transfection of one complete 6-well plate before determined to be
unsuccessful.
Plaque assays
Plaque assays for LACV and rLACVs were performed in VERO cells,
an African green monkey kidney cell line. VERO cells were plated
overnight at 3×105 cells/well in a 6 well plate and serial dilutions of
cell culture supernatants (10−2 to 10−6) and uninfected control
supernatants were applied for 1 h. The diluted culture supernatants
were then removed and a 1:1 mixture of 2% carboxymethyl-cellulose
(Sigma-Aldrich, Saint Louis, MO) and 2× DMEM (Gibco) and 4% fetal
calf serum were added. VERO cells were incubated for 72 h at 32 °C,
10% CO2 before the carboxymethyl-cellulose overlay was removed.
Plaques were then visualized by staining with 0.1% crystal violet.
Expression of wild-type and mutant LACV Gc in cells infected by
recombinant LACVs: detection by ﬂow cytometry
BHK-21s, Hela and C6/36 cells were harvested and ﬁxed for
30 min in a 2% paraformaldehyde solution. Non-speciﬁc binding was
reduced by exposure to 10% goat serum (Sigma, St. Louis, MO) for
30 min. Cells were then washed three times in ﬂuorescence-activated
cell sorter (FACS) stain buffer (PBS with 1% FCS and 0.1% sodium
azide) prior to incubation at room temperature for 60 min with either
a 1:100 dilution of conformation dependent MAbs 807-31 and 807-22
against LACV Gc (50:50, vol/vol), or a commercial MAb against LACV
Gn (Abcam, Cambridge, MA). For each experiment, an aliquot of cells
was also treated with isotype-matched control antibodies to establish
background staining. The cells were then washed three times in FACS
stain buffer and incubated at room temperature with a 1:100 dilution
of a FITC conjugated anti-mouse IgG (Sigma) for 30 min. After
incubation with the FITC conjugated secondary antibody, cells were
washed three times in FACS stain buffer and resuspended in 400 µl
FACS stain buffer before acquisition and analysis on a FACScalibur
instrument (Becton Dickinson, Sunnyvale, CA) using FlowJo software
(University of Pennsylvania Cancer Center).
Fusion from within assay (FFWI)
FFWI was performed as described previously (Gonzalez-Scarano
et al., 1985; Pobjecky et al., 1986). BHK-21, C636, and differentiated
G8 cells were plated at a concentration of 1×105 cells per well inpoly-L-lysine (Sigma) pre-coated 24 well plates. Subconﬂuent mono-
layers of cells were then inoculated at a multiplicity of infection of
1.0 pfu/cell, incubated for 1h, washed with PBS and incubated with
DMEM plus 2% FCS (infectionmedium) for 18 h at 35 °C. At that point,
cells were washed again with PBS and then exposed to medium
(serum free DMEM with 10 mM morpholinoethanesulfonic acid
adjusted to the appropriate pH with NaOH). The acidic medium was
replaced with maintenance medium after 30–60 s and the cells were
further incubated at 37 °C (or at other temperatures for experiments
described in Fig. 5) for 30 min. The cells were then ﬁxed and stained
with Giemsa (Difco Laboratories, Detroit, MI), and counted. The fusion
index (FI) was determined as FI=1−(C/N) where C and N are the
numbers of cells and nuclei, respectively.
Preparation of primary neuronal cultures
Primary rat neuronal cultures were prepared from embryonic day
17 Sprague Dawley rat pups as described previously (Brewer, 1995).
Cells were plated on plates or German glass coverslips pre-coated
with poly-L-lysine (Sigma) at a density of 4×104 cells per well in a 96
well plate or at a density of 2×105 cells per well in a 24 well plate and
maintained inneurobasalmediumsupplementedwithB27 (Invitrogen)
at 37 °C, 5% CO2. Primary rat neuronal cultures were infectedwith LACV
at 7 days in vitro (DIV).
Quantiﬁcation of LACV induced neurotoxicity
Microtubule associate protein 2 (MAP2) cell-based ELISA
A MAP2 cell-based ELISA assay was used to quantify neuronal
death as previously described (Wang et al., 2007). This MAP2 cell-
based ELISA has been demonstrated to produce results similar to
those produced by hand quantiﬁcation of MAP2 positive neurons
(O'Donnell et al., 2006;Wang et al., 2007). Brieﬂy, primary rat cortical
neuroglial cultures were plated in poly-L-lysine-coated 96 well plates
at a concentration of 4×104 cells per well. Forty-eight hours after
infection with LACV or rLAVCs at day in vitro (DIV) 7 at a M.O.I. of 1.0,
cells were ﬁxed for 30 min with 4% paraformaldehyde in 4% sucrose.
After blocking for 1h with 5% normal goat serum in PBS, the plates
were incubated with mouse anti-MAP2 antibody (1:1000 dilution)
overnight at 4 °C, followed by washing with PBS-Tween. The plates
were then incubated for 30 min with goat anti-mouse secondary
antibody conjugated to beta-lactamase TEM-1 (1:500), washed, and
incubated at 23 °C for 60 min with 0.5 µg Fluorocillin™ Green
substrate per well. Fluorescence intensity was measured using a
Fluoroskan Ascent ﬂuorometer plate reader (Thermo Electron,
Waltham, MA, USA) with excitation at 485 nm and emmission at
527 nm. Relative changes in the intensity of the ﬂuorescent MAP2
signal were used to estimate neuronal damage; n=10 replicates per
condition.
Immunoﬂuorescence Assay (IFA) for MAP2 and LACV detection
Primary cortical neuroglial cultures were plated in poly-L-lysine-
coated 96well plates at a concentration of 4×104 cells per well. Forty-
eight hours after infection with LACV or rLAVCs at day in vitro (DIV) 7
at an M.O.I. of 1.0, cells were ﬁxed for 30 min with 4% paraformal-
dehyde in 4% sucrose in PBS for 1h followed by permeabilization in
100% methanol (10 min) and 0.2% Triton X-100/PBS (10 min).
Cultures were then washed twice with PBS, blocked with 10% goat
serum in PBS (45 min at room temperature), and then exposed to
anti-MAP2 antibody (60 µM in 10% goat serum in PBS) and a 1:500
dilution of pre-adsorbed rabbit anti-LACV Gc antibody for 1 h at room
temperature. After washing, a tetrametylrhodamine isothiocyanate
(TRITC) conjugated goat anti-IgG secondary antibody (66 µM; 45 min
at room temperature) was used for detection of MAP2 antibody
binding and a ﬂuorescein isothiocyanate (FITC) conjugated anti-rabbit
147S.S. Soldan et al. / Virology 404 (2010) 139–147IgG antibody (1:100) was used for the detection of LACV antibody
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